Health Systems, Economic Evaluations, Quality of Life

Работ: 58

Identification of Bioactive Compounds of the Endophytic Fungus <i>Aspergillus egypticus</i>-HT166S Inhibiting the Activity of Pancreatic α-Amylase
D. M. Ruzieva, T.G. Gulyamova, Saodat Nasmetova +2
СтатьяComputational Drug Discovery MethodsTurkish Journal of Pharmaceutical Sciences2021Цитирований: 0
ABI
Pharmacoeconomics and the Patients’ Compliance as an Essential part of Successful therapy of iron Deficiency Anemia.
Khodjieva Gulirano Sayfullaevna
СтатьяHealth Systems, Economic Evaluations, Quality of LifeIndonesian Journal of Innovation Studies2022Цитирований: 0
ABI
POS-592 COMPARATIVE ANALYSIS OF THE CAUSES OF DEATH IN DIALYSIS PATIENTS WITH AND WITHOUT CARDIOVASCULAR DISEASES
Olimkhon Sharapov, Botir Daminov, Sherzod Abdullaev
СтатьяBlood Pressure and Hypertension StudiesKidney International Reports2022Цитирований: 0
ABI
Case in clinical practice: Modern intensive care in the treatment of post-resuscitation complications caused by cardiac arrhythmias
Khayitov Dilshod Khayotovich, Boltayev Elmurod Bekmurodugli
СтатьяCardiac electrophysiology and arrhythmiasACADEMICIA An International Multidisciplinary Research Journal2022Цитирований: 0
ABI
What Is the Scope of Fair and Equitable Treatment (FET) Standard, What Is the Effect or Its Alleged Breadth?
Saidyakhyo Usmankhodjaev
СтатьяHealth Systems, Economic Evaluations, Quality of LifeSSRN Electronic Journal2023Цитирований: 0
ABI
The reported impact of non-communicable disease investment cases in 13 countries
Giuseppe Troisi, Roy Small, Roman Chestnov +36
СтатьяGlobal Public Health Policies and EpidemiologyBMJ Global Health2024Цитирований: 0
ABI
Bradford Assay v1
Jailyn Izu
ПрепринтHealth Systems, Economic Evaluations, Quality of Life2024Цитирований: 0
ABI
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Fotios Barkas, Yusuf Ziya Şener, Pelin Golforoush +25
Обзорная статьяLipoproteins and Cardiovascular HealthAtherosclerosis2024Цитирований: 0
ABI
Drug-drug interactions in clinical practice: a literature review and SWOT analysis
Valeriya O. Barysheva, О. S. Golikova, В. Г. Кудрина +1
Обзорная статьяPharmaceutical Practices and Patient OutcomesMedical Technologies Assessment and Choice2024Цитирований: 0
ABI
Defining Health Management: A Conceptual Foundation for Excellence Through Efficiency, Sustainability and Equity
George Valiotis, Sandra C. Buttiġieġ, Americo Cicchetti +12
СтатьяHealth Systems, Economic Evaluations, Quality of LifeThe International Journal of Health Planning and Management2025Цитирований: 0
ABI
Determining Indicators of Medical Care Quality in Private Health Institutions
G. A. Kabilova
СтатьяHealth Systems, Economic Evaluations, Quality of LifeAcademia Open2025Цитирований: 0
ABI
Optimizing Healthcare Quality Through ISO 9001:2015 and ISO 7101:2023 Standards
Komilov Bekzodbek Maxmudjon Ugli
СтатьяQuality and Supply ManagementAcademia Open2025Цитирований: 0
ABI
Dual‐Criterion Approach Incorporating Historical Information to Seek Accelerated Approval With Application in Time‐to‐Event Group Sequential Trials
Marco Ratta, Gaëlle Saint‐Hilary, Valentine Barboux +3
СтатьяAdvanced Causal Inference TechniquesStatistics in Medicine2026Цитирований: 0
ABI
Rare diseases as a global priority: the CIS Orphan Forum and the path toward collaboration with BRICS
Nuriya Z. Musina, Ahmed Al Saidi, Ayman W. El-Hattab +27
СтатьяGenomics and Rare DiseasesThe BRICS Health Journal2026Цитирований: 0
ABI
Advancing global health economics and policy of palliative and end-of-life care: insights from Ireland, Norway, Finland, Argentina, and India
Claudia Fischer, Gudrun Waaler Bjørnelv, Rui Dang +2
СтатьяGlobal Health Care IssuesAnnals of Palliative Medicine2026Цитирований: 0
ABI
valuation
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
theykch valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI
valuation framework
Yoshimitsu Katayama
ПрепринтHealth Systems, Economic Evaluations, Quality of LifeZenodo (CERN European Organization for Nuclear Research)2026Цитирований: 0
ABI